New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2012
10:39 EDTESRX, MHSExpress Scripts, Medco climb after report says FTC likely to approve deal
The Federal Trade Commission, or FTC, staff is expected to recommend that the regulator approve Express Scripts' (ESRX) proposed acquisition of its pharmacy benefit management rival, Medco (MHS), according to market intelligence journal MLex, which cited unnamed sources. However, the FTC may still mount a legal challenge to the deal, adds the publication. The agency has been challenging healthcare mergers, and has been especially vigilant in its regulation of the pharmacy benefit management sector, notes MLex. The issue is likely to be decided by FTC Chairman Jon Leibowitz, who worked as Senator Herb Kohl's leading antitrust advisor for years, the publication said. In mid-morning trading, Medco rose $1.39, or 2.28%, to $62.33, while Express Scripts climbed $1.45, or 2.91%, to $51.24.
News For MHS;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:22 EDTESRXExpress Scripts CFO change a 'modest' concern, says Leerink
Subscribe for More Information
07:47 EDTESRXExpress Scripts new CFO experience reassuring, says Oppenheimer
Subscribe for More Information
December 15, 2014
16:40 EDTESRXExpress Scripts backs FY14 EPS view $4.86-$4.90, consensus $4.88
Subscribe for More Information
16:39 EDTESRXExpress Scripts increases share repurchase authorization by 65M shares
Subscribe for More Information
16:37 EDTESRXExpress Scripts CFO Cathy Smith leaving company
Subscribe for More Information
07:40 EDTESRXExpress Scripts price target raised to $96 from $82 at UBS
Subscribe for More Information
December 8, 2014
11:30 EDTESRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use